• To prove advanced gastric cancer patients after neoadjuvant chemotherapy should have better disease-free survival than adjuvant chemotherapy patients, RESONANCE trial was designed and registered. (omicsonline.org)
  • Therefore, it may be appropriate to include the ADOC therapy as adjuvant therapy for patients undergoing surgery for thymoma. (readabstracts.com)
  • Patients undergoing surgical treatment may benefit from either adjuvant therapy, in which the ADOC treatment is given after surgery, or neoadjuvant chemotherapy, in which the ADOC treatment is administered in preparation for surgery. (readabstracts.com)
  • 20 - 25 ] A major pooled analysis evaluating the impact of T and N stage and treatment on survival and relapse in patients with rectal cancer who are treated with adjuvant therapy confirmed these findings. (cancer.gov)
  • Mismatch repair-deficient tumors do not respond well to chemotherapy applied in the neoadjuvant, adjuvant, or metastatic settings. (cancer.gov)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • Adjuvant chemotherapy consisted of four cycles of fluorouracil-based regimens. (bepress.com)
  • Eighteen patients received adjuvant chemotherapy as a component of primary treatment (9 FIGO stage I, 9 stage II - IV) and seven after recurrence. (thieme-connect.de)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • To assess the feasibility of QOL assessment in a cohort of Tunisian cancer patients, the EORTC QLQ-C30 questionnaire was administered to 23 women treated with adjuvant chemotherapy for early breast cancer on an outpatient basis at baseline and during the 3rd cycle of chemotherapy. (who.int)
  • Depending on each large tumours and/or histologically proven patient's education level, the questionnaire axillary lymph node involvement requiring was either self-completed or administered adjuvant cytotoxic chemotherapy. (who.int)
  • assess the feasibility of QOL evaluation in a The QLQ-C30 was assessed by the same cohort of Tunisian women with early breast physician (A.M.) at 2 points of time: just cancer receiving adjuvant chemotherapy. (who.int)
  • After surgical removal of the primary tumor, breast cancer patients are frequently treated with radiotherapy, hormone therapy and cytotoxic chemotherapy to reduce the risk of recurrence. (justia.com)
  • BT-ON014 trade name] treatment should only be initiated by a health care provider experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a health care provider only. (who.int)
  • Neoadjuvant chemotherapy has some advantages over postoperative chemotherapy in advanced cancer patients, represented by primary tumor downstaging, testing chemotherapy sensitivity and controlling distant micrometastasis. (omicsonline.org)
  • From March 1, 2012 to January 14, 2013, eighty- one gastric cancer patients were enrolled in RESONANCE trial as neoadjuvant chemotherapy arm. (omicsonline.org)
  • RTOG 0247 was a randomized, Phase II multicenter trial of patients with locally advanced (T3 and T4) rectal cancer treated with neoadjuvant chemoradiation from March 2004 to February 2007. (appliedradiationoncology.com)
  • The primary endpoint analysis of RTOG 0247 examined the pathologic complete remission (pCR) rates of two concurrent neoadjuvant chemotherapy regimens to determine which regimen should be studied further. (appliedradiationoncology.com)
  • Conclusions: This first large randomized trial suggests high efficacy and excellent tolerability of a neoadjuvant nabpaclitaxel/carboplatin regimen, superior to nab-paclitaxel/gemcitabine in TNBC. (uni-koeln.de)
  • This small sample data showed most of AJCC II-III stage gastric cancer patients could benefit from preoperative SOX regimen chemotherapy and long-term survival needed to be expected. (omicsonline.org)
  • In this study, we sought to investigate apatinib combined with conventional chemotherapy regimens in treating patients with advanced TNBC concerning the efficacy, safety, expressions of tumor markers, and patient survival. (scienceopen.com)
  • Most economic evaluations of chemotherapies for ovarian cancer patients have used hypothetical cohorts or randomized control trials, but evidence integrating real-world survival, cost, and utility data is limited. (rti.org)
  • Improvements in chemotherapy have, in recent decades, increased the survival time for patients with multiple myeloma. (readabstracts.com)
  • Although long-term survival is possible for patients with multiple myeloma, the disease is never considered cured, since the threat of relapse never entirely disappears. (readabstracts.com)
  • This finding suggests that the omission of maintenance therapy may be made without undue risk to the patients' survival. (readabstracts.com)
  • The results of this study indicate that multiple patients may omit maintenance chemotherapy without adversely affecting their chances for survival. (readabstracts.com)
  • The median survival time for all the patients was 15 months, and the survival of individual patients ranged from five to over 96 months. (readabstracts.com)
  • Over half of the patients who achieved complete remissions are still alive, and therefore it is not yet possible to evaluate the median survival for this group. (readabstracts.com)
  • A 2011 study published in the New England Journal of Medicine found that FOLFIRINOX produced the longest improvement in survival ever seen in a phase III clinical trial of patients with advanced pancreatic cancer, with patients on the FOLFIRINOX treatment living approximately four months longer than patients receiving the standard gemcitabine treatment (11.1 months compared with 6.8 months). (wikipedia.org)
  • Better survival of patients with early-stage lesions. (cancer.gov)
  • The 2-year survival of patients who were treated with chemotherapyand radiation therapy was 36%, said Dr. Ritsuko Komaki, co-chairof RTOG 91-06. (cancernetwork.com)
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • Although several studies have shown partial or even complete remission, there is no convincing evidence that systemic therapy will improve the survival duration of patients with adrenal cancer. (cancer.gov)
  • Radical open surgical excision is the treatment of choice for patients with localized malignancies and remains the only method by which long-term disease-free survival may be achieved. (cancer.gov)
  • Although the number of patients was small, there was no significant difference in overall survival between patients who received platinum-based regimens and those who received chemotherapy without platinum. (thieme-connect.de)
  • 2 Björkholm E. Granulosa cell tumor: A comparison of survival in patients and matched controls. (thieme-connect.de)
  • The team combined their genetic data and those from previous studies and found through advanced analysis that lymphoma patients with DDX3X mutations had a significantly lower survival rate than those without such mutations. (eurekalert.org)
  • Although further research is needed, these findings provide hope that new and better drugs could be developed to block STAT activity and therefore improve the chances of survival for non-Hodgkin lymphoma patients with DDX3X mutations. (eurekalert.org)
  • Published in the scientific journal Molecular Cancer in October 2021, the findings shed light on aggressive forms of non-Hodgkin lymphoma and provide insights into possible new therapy options for this group of patients with poor chances of survival. (eurekalert.org)
  • After approximately 23 months of follow-up, the median progression-free survival was not reached in the Venclexta arm but was 18.1 months with the chemotherapy regimen. (curetoday.com)
  • The approval of the combination of Venclexta plus rituximab for patients with relapsed/refractory CLL or SLL validates the results seen in the phase 3 trial, including the significant improvement in progression-free survival over a standard of care comparator arm,' lead investigator John Seymour, Ph.D., MBBS, director of cancer medicine at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Australia, said in the release. (curetoday.com)
  • Patients are followed for survival. (knowcancer.com)
  • Objective To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. (thieme-connect.de)
  • Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. (thieme-connect.de)
  • For this center, we have survival information for 112 patients. (bethematch.org)
  • The actual 1-year survival of these patients is 78.6% . (bethematch.org)
  • For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov. (bethematch.org)
  • Various combination regimens have shown improved response rates in several randomized trials but also have failed to show any survival advantage. (medscape.com)
  • Approval was based on results from the Phase III AURELIA study, which showed that adding bevacizumab to chemotherapy significantly improved progressive-free survival (PFS) and overall response rate (ORR). (medscape.com)
  • The addition of consolidation chemotherapy, consolidation whole-brain radiation therapy, or high-dose chemotherapy with stem-cell rescue may improve survival. (msdmanuals.com)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
  • p53, mdm-2, p21, and mib-1 expression were not significantly associated with response to chemotherapy, time to progression, or overall survival in the whole patient population or in the docetaxel group. (lu.se)
  • This study provides a detailed description of current breast cancer management in sub-Saharan Africa, which is the region with the lowest survival rates for patients with breast cancer in the world. (who.int)
  • This is the first study to demonstrate the efficacy of EMEND in men and women treated with a broad range of moderately emetogenic chemotherapy regimens for various types of cancer," said Bernardo Rapoport, MD, Medical Oncology Center of Rosebank, Johannesburg, South Africa. (hospitalhealthcare.com)
  • 1 ] MOC treatment is the same as other histological subtypes, i.e., upfront debulking surgery where possible, followed by platinum-based chemotherapy when indicted. (thieme-connect.de)
  • New data presented today at the American Society of Clinical Oncology (ASCO) annual meeting show that EMEND® (aprepitant), administered in combination with a standard antiemetic regimen, is 76.2% effective in preventing chemotherapy-induced nausea and vomiting in men and women with a broad range of tumour types receiving a range of moderately emetogenic chemotherapy (MEC). (hospitalhealthcare.com)
  • [ 8 ] In patients receiving moderately emetogenic chemotherapy (MEC), better CINV control was obtained with palonosetron than with a first-generation 5-HT 3 RA, [ 9 ] which supports current guideline recommendations for palonosetron use as a part of antiemetic premedication for MEC. (medscape.com)
  • Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment. (stanford.edu)
  • With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumor-treating fields will be presented. (cancernetwork.com)
  • At the same time the patient receives also radiotherapy to the metastases in the liver or in the brain. (nethealthbook.com)
  • Accodrding to Japanese Gastric Cancer Association histological evaluation criteria of tumor response after preoperative therapy, 7 patients achieved Grade 3 response (complete response), 20 patients Grade 2 response, 9 patients Grade 1 response, 1 patient Grade 0 response. (omicsonline.org)
  • The present invention relates to methods, kits and systems for predicting the benefit from inclusion of taxane in a chemotherapy regimen based on the measurements of gene expression levels in tumor samples of breast cancer patients. (justia.com)
  • The most challenging treatment decision in this context concerns ER+/HER2-breast cancer patients, for which classical clinical factors like grading, tumor size or lymph node involvement do not provide a clear answer to the question whether to use chemotherapy or not and what type of treatment therapy is appropriate for the individual patient. (justia.com)
  • Due to the absence of specific treatment strategies for this tumor subgroup, patients with TNBC are treated with conventional therapeutics, frequently leading to systemic relapse. (scienceopen.com)
  • Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing. (stanford.edu)
  • Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment initiation. (stanford.edu)
  • Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. (biomedcentral.com)
  • One patient who had 50-gene panel only also had his metastatic site (esophagus) of his tumor tested with FoundationOne. (cancerindex.org)
  • Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. (medscape.com)
  • High tumor proliferation has previously been associated with response to chemotherapy. (lu.se)
  • Although highly preliminary, the findings suggest that different tumor biological factors may predict response to different chemotherapy regimens with distinct mechanisms of action. (lu.se)
  • The results of our phenotype analysis also indicate that it is more likely that a panel of tumor biological factors instead of only one single factor may be needed for better prediction of chemotherapy response. (lu.se)
  • Patients with a malignant solid tumor who would receive HEC containing 50 mg/m 2 or more cisplatin were randomly assigned to either palonosetron (0.75 mg) arm (Arm P) or granisetron (1 mg) arm (Arm G), on day 1, both arms with dexamethasone (12 mg on day 1 and 8 mg on days 2-4) and aprepitant (125 mg on day 1 and 80 mg on days 2-3). (medscape.com)
  • Increasing age and decreasing cell-mediated immunity as a result of transplantation, chemotherapy, or other immunosuppressive medications (e.g., tumor necrosis factor-α inhibitors) are the main predisposing factors ( 1 , 2 , 9 ). (cdc.gov)
  • Currently FOLFIRINOX is being used to downstage patients with "borderline and locally advanced" disease with the hope of rendering their tumors amenable to surgical resection. (wikipedia.org)
  • Patients treated with radiationtherapy alone had similar nodal stage distribution, but somewhatsmaller tumors. (cancernetwork.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • Patients who have low-grade tumors without evidence of invasion into local tissues or spread to lymph nodes have an improved prognosis. (cancer.gov)
  • Unresectable or widely disseminated tumors may be palliated by adrenolytic therapy with mitotane, antihormonal drugs (i.e., ketoconazole and metyrapone), systemic chemotherapy, and/or radiation therapy. (cancer.gov)
  • range, 26 - 75) who received chemotherapy after surgery for ovarian granulosa cell tumors. (thieme-connect.de)
  • The rarity of ovarian granulsa cell tumors suggests a need for a central registry and prospective studies to compare chemotherapy regimens. (thieme-connect.de)
  • Former series of long-term survivors are commonly enriched for patients with IDH -mutated tumors. (cancernetwork.com)
  • What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? (medscape.com)
  • Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. (medscape.com)
  • p53, mdm-2, p21, and mib-1 expression were assessed by immunohistochemical methods in primary tumors derived from 134 patients who took part in a randomized multicenter trial comparing docetaxel to sequential methotrexate and 5-fluorouracil (MF) in advanced breast cancer. (lu.se)
  • Cisplatin-based highly emetogenic chemotherapy (HEC) regimens, which are key treatments for some of malignant tumors, were conventionally administered after an antiemetic premedication with dexamethasone plus a 5-hydroxytryptamine 3 receptor antagonist (5-HT 3 RA) such as ondansetron or granisetron. (medscape.com)
  • Today, anthracycline and taxane-based treatment strategies are commonly used in clinical routine, since these regimens have been shown to be superior compared to other standard chemotherapies. (justia.com)
  • The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. (rxlist.com)
  • De-escalation of further chemotherapy in patients with early pCR after a short anthracycline-free regimen is a promising field of future research. (uni-koeln.de)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • Our new analysis of RTOG 0247 provides us with favorable efficacy results of two preoperative chemotherapy regimens used in conjunction with radiation therapy protocols," said Neal J. Meropol, MD, co-author of the study, and the Dr. Lester E. Coleman Jr., Professor of Cancer Research and Therapeutics and chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center and Case Western Reserve University in Cleveland. (appliedradiationoncology.com)
  • This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. (stanford.edu)
  • Furthermore, they can lead to delays and dose reductions in chemotherapy treatment, thereby potentially compromising the efficacy of chemotherapy and, consequently, patient outcome [ 10 ]. (hindawi.com)
  • The purpose of these methods is to enable functional testing of patient specific efficacy of a. (biomedcentral.com)
  • The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers. (businesswire.com)
  • OBJECTIVES: I. Determine the efficacy and toxicity of SU5416 combined with interferon alfa-2b in patients with unresectable or metastatic renal cell carcinoma. (knowcancer.com)
  • The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear. (medscimonit.com)
  • TDM in colorectal cancer can reduce toxicity, improve efficacy and clinical outcome, and can be routinely used in 5-FU-based chemotherapy. (medscimonit.com)
  • There has been no phase III study of comparing the efficacy of first- and second-generation 5-HT 3 receptor antagonists in the triplet regimen with dexamethasone and aprepitant for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy (HEC). (medscape.com)
  • APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the prevention of CINV (MAGIC) trial. (nih.gov)
  • highly emetogenic chemotherapy (HEC). (nih.gov)
  • To reduce the number of patients suffering from side effects without a clear benefit of the therapy regimen, there is a great need for novel predictive tests to identify a group of patients that can be safely treated with conventional chemotherapy and a subgroup that has a significant benefit of taxane-based treatment. (justia.com)
  • In patients with multiple myeloma it is not clear that maintenance therapy is effective. (readabstracts.com)
  • Twenty-six of 38 patients responded to the second treatment, a response rate less than that for the initial therapy. (readabstracts.com)
  • All patients received preoperative pelvic radiation therapy of 50.4 Gy over five-and-a-half weeks, with 45 Gy delivered in 25 fractions (1.8 Gy per fraction, five fractions per week for five weeks) and a boost of 5.4 Gy in three fractions. (appliedradiationoncology.com)
  • Patients were randomized to two chemotherapy treatment arms concurrent to their radiation therapy: Patients in arm 1 received concurrent chemotherapy consisting of four doses of irinotecan (50 mg/m2 IV weekly) and capecitabine (1200 mg/m2/d orally Monday through Friday during radiation therapy). (appliedradiationoncology.com)
  • Patients in arm 2 received concurrent chemotherapy consisting of five doses of oxaliplatin (50 mg/m2 IV weekly) and capecitabine (1600 mg/m2/d orally Monday through Friday during radiation therapy). (appliedradiationoncology.com)
  • All patients in each arm had surgery four to six weeks after completion of radiation therapy, and all patients in both arms had postoperative chemotherapy of FOLFOX four to six weeks after surgery. (appliedradiationoncology.com)
  • Patient evaluations occurred weekly during concurrent chemotherapy and radiation therapy, before surgery and before each cycle of postoperative chemotherapy. (appliedradiationoncology.com)
  • Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum based therapy. (stanford.edu)
  • Patients with a history of immunodeficiency (except for acquired hypogammaglobulinemia), patients with active autoimmune disease requiring systemic immunosuppressive therapy (i.e. (moffitt.org)
  • 15 mg of prednisone daily or equivalent), or patients who have received any other form of immunosuppressive therapy within 7 days prior to leukapheresis. (moffitt.org)
  • The addition of cisplatin (Platinol) and oral etoposide (VePesid)to radiation therapy delays distant metastasis, thus increasingsurvival of patients with inoperable non-small-cell lung cancer,a comparison of RTOG 91-06 to RTOG 83-11 shows. (cancernetwork.com)
  • That compares to 22% for patients treated withhyperfractionated radiation therapy alone. (cancernetwork.com)
  • Patients treated with combined therapy had either stage IIIa orIIIb or medically inoperable stage II non-small-cell lung cancer.They were given 50 mg/m² of cisplatin on days one and eightof treatment. (cancernetwork.com)
  • The rates of life-threatening nonhematologic toxicity were similarfor both groups of patients (2.6% for the combined treatment;3.0% for radiation therapy alone). (cancernetwork.com)
  • Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy. (cancernetwork.com)
  • Molecular heterogeneity is one of the most important concerns in colorectal cancer (CRC), which results in a wide range of therapy responses and patient prognosis. (biomedcentral.com)
  • Three patients had disease progression prior to therapy, and 69 patients were analyzed. (bepress.com)
  • Uncontrolled nausea and vomiting can limit the effectiveness of cancer therapy and reduce patient quality of life. (hospitalhealthcare.com)
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • In the past two decades, therapy for newly diagnosed APL has evolved from an all- trans retinoic acid (ATRA)+chemotherapy backbone for all patients to the addition of arsenic trioxide (ATO) to ATRA with omission of chemotherapy in low-risk patients as a new standard of care. (nature.com)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see DOSAGE AND ADMINISTRATION ]. (rxlist.com)
  • However, majority of patients with aggressive forms of non-Hodgkin lymphoma do not respond to traditional therapy, and a sub-group of patients who respond initially go on to relapse and progress to fatal outcomes. (eurekalert.org)
  • Early identification will allow clinicians to have a better understanding of general chemotherapy outcome for this group of cancer patients and enable them to offer personalised therapy from the get-go, buying precious time that would otherwise be spent on futile chemotherapy. (eurekalert.org)
  • The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy. (curetoday.com)
  • The agency based its decision on data from the randomized, multicenter, open-label phase 3 MURANO trial - designed to evaluate Venclexta plus Rituxan compared with a standard of care chemoimmunotherapy regimen - bendamustine plus Rituxan - in 389 patients with CLL who had received at least one prior line of therapy. (curetoday.com)
  • The FDA previously granted an accelerated approval to the BCL-2 inhibitor, manufactured by AbbVie and Genentech, in combination with Rituxan for patients with CLL/SLL harboring a 17p deletion following at least one prior therapy. (curetoday.com)
  • The researchers excluded patients who could not stand or walk without assistance, had a prior diagnosis of any type of neuropathy, and were exposed to other medications known to cause neuropathy (eg, vinblastine, bortezomib, platinum therapy) within the past year. (oncologynurseadvisor.com)
  • About 80% of patients do not need any further therapy than this. (nethealthbook.com)
  • The strategic approach that had been taken had also resulted in significant improvements in work to prevent and control leprosy, such as simplification of diagnosis and multidrug therapy through provision of blister packs free to all new patients. (who.int)
  • Since 1985, more than 15 million patients have been cured through multidrug therapy. (who.int)
  • At the beginning of 2010, that figure had fallen further to 212 000 cases, corresponding to the number of patients on multidrug therapy at that time. (who.int)
  • The current multidrug therapy regimens remain the mainstay of leprosy chemotherapy implemented in all countries where leprosy is endemic. (who.int)
  • Preliminary results of an ongoing trial raise the prospect of reducing the duration of multidrug therapy currently recommended by WHO to six months for patients with multibacillary leprosy but it is still too early to draw final conclusions. (who.int)
  • We have also successfully treated many patients with the newly innovative Car-T Cellular therapy with both FDA approved as well as clinical trial products We are experts in the field of haplo identical transplants with great success. (bethematch.org)
  • Treatment includes corticosteroids, chemotherapy, and radiation therapy. (msdmanuals.com)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Compared with years past, older adults today are more likely to be considered for transplantation, receive aggressive regimens of chemotherapy, or take immunosuppressive drugs for rheumatologic or autoimmune diseases. (cdc.gov)
  • 1. PM from histologically confirmed primary epithelial ovarian, tubal, or primary peritoneal platinum-resistant carcinoma (including clinical recurrence, refractory disease, or persistent disease within 6 months of last chemotherapy). (who.int)
  • In addition, the same treatment regimen was effective when used a second time in the relapsed patients. (readabstracts.com)
  • His treatment regimen has included chemotherapy, radiation, and surgery. (digitalmusicnews.com)
  • To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites. (aacrjournals.org)
  • Patients with recurrent malignant glioma received a fixed dose of temozolomide (150 mg/m 2 ) daily for 5 days from days 1 to 5 every 28 days, and an i.v. infusion of irinotecan on days 1 and 15 of each cycle. (aacrjournals.org)
  • Used both as single agent and in multiagent regimens for the treatment of malignant GTN. (medscape.com)
  • Use as single agent or as part of multiagent regimen for treatment of malignant GTN. (medscape.com)
  • Effective antineoplastic used in patients with chemotherapy-resistant malignant GTN. (medscape.com)
  • Single-agent treatment is the preferred approach for patients with platinum-resistant disease or for patients with intermediate platinum-sensitive disease with a short time to recurrence of 6-12 months. (medscape.com)
  • We evaluated carboplatin vs gemcitabine with a nab-paclitaxel backbone as a short 12-week A-free regimen with a focus on early response. (uni-koeln.de)
  • Among the 394 enrolled patients the incidence of grade 3-4 neutropenia was 16.2% and of febrile neutropenia was 1.5%, far lower than the reported 85-100% and 30-40% incidence without G-CSFs. (hindawi.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • Incidence of primary brain lymphomas is increasing, particularly among immunocompromised patients and older people. (msdmanuals.com)
  • Although can- number of positive axillary lymph nodes cer incidence is increasing in the developing and chemotherapy regimen. (who.int)
  • Hospitalization rates for adults were described per region, but incidence rates, specifically for older patients, were not available. (cdc.gov)
  • The initial results demonstrated that patients who received irinotecan plus capecitabine had lower pCR rates (10 percent compared to those who received oxaliplatin plus capecitabine (21 percent). (appliedradiationoncology.com)
  • At four-year follow-up, patients in arm 2 (oxaliplatin plus capecitabine) had an OS rate of 75 percent (39), a DFS rate of 62 percent (32), a LRF rate of 18 percent (9), a DF rate of 30 percent (16) and an SP rate of 6 percent (3). (appliedradiationoncology.com)
  • Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. (amgen.com)
  • Vectibix in combination with oxaliplatin-based chemotherapy is not indicated for the treatment of patients with RAS ( KRAS or NRAS ) mutation-positive mCRC or for whom RAS status is unknown. (amgen.com)
  • In December 2007 , the European Medicine Agency (EMA) granted a conditional marketing authorization for Vectibix as a monotherapy for the treatment of patients with EGFR-expressing mCRC with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. (amgen.com)
  • All these patients were in AJCC II-III stages, evaluated by CT, EUS, and laparoscopic exploration and were administered preoperative 2 to 4 cycles SOX regimen chemotherapy. (omicsonline.org)
  • Multidrug chemotherapy regimens including high-dose IV methotrexate (1 g/m2 to 8 g/m2) may result in long-lasting responses. (msdmanuals.com)
  • Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. (justia.com)
  • Treatment regimens (i.e., no chemotherapy, platinum-based only, platinum plus taxane, and other nonplatinum) were identified in the 6 months postdiagnosis. (rti.org)
  • On comparing the platinum-based group versus no chemotherapy, we found that the ICER was $30,073/QALY and $58,151/QALY for early- and late-stage disease, respectively, while other nonplatinum and platinum plus taxane groups were dominated (less effective and more costly). (rti.org)
  • For patients 85 years or older, platinum plus taxane, however, was not dominated by the platinum-based group, with an ICER of $133,892/QALY. (rti.org)
  • The recently published study involving patients with breast cancer receiving taxane-based chemotherapy identified the extent of the problem. (oncologynurseadvisor.com)
  • Researchers from The Ohio State University and Mayo Clinic sought to describe the natural histories of patient-reported CIPN symptoms and functional impairments in patients with breast cancer receiving taxane-based chemotherapy. (oncologynurseadvisor.com)
  • All participants were starting on taxane-based chemotherapy regimen. (oncologynurseadvisor.com)
  • Questions have been raised concerning the use of maintenance chemotherapy for patients with multiple myeloma. (readabstracts.com)
  • Maintenance chemotherapy is chemotherapy that is given after a complete response has been induced to lengthen the period of remission. (readabstracts.com)
  • It was possible to again achieve a response in 7 of 16 patients who received the chemotherapeutic regimen for a third time. (readabstracts.com)
  • The results obtained with the ADOC chemotherapeutic regimen are superior to the reported successes achieved with other treatment methods. (readabstracts.com)
  • The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy. (ahrq.gov)
  • Based on this evidence, guidelines published by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer state that when the overall risk of FN is 20% or greater, especially on "dose dense" regimens, primary prophylaxis with G-CSFs is justified [ 10 , 13 ]. (hindawi.com)
  • [ 3 , 4 ] Current antiemesis guidelines from multiple organizations [American Society of Clinical Oncology (ASCO), Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO), and National Comprehensive Cancer Network (NCCN)] recommend aprepitant-containing triplet regimens as the standard antiemetic prophylaxis for patients receiving HEC. (medscape.com)
  • The median follow-up for patients in arm 1 was 3.77 years (range 0.19 to 5.23 years), and the median follow-up for patients in arm 2 was 3.97 years (range 0.44 to 5.15 years). (appliedradiationoncology.com)
  • Radiation treatments were started within 96 hours of chemotherapy,to a total dose of 69.6 Gy in 58 fractions over 29 days, 2 fractionsper day, at least 6 hours apart. (cancernetwork.com)
  • EMEND is the first in a new class of antiemetic treatments called neurokinin 1 (NK1) receptor antagonists that treat chemotherapy-induced nausea and vomiting. (hospitalhealthcare.com)
  • It is believed to work by directly blocking the nausea and vomiting signals to the brain caused by chemotherapy agents - different from all other antiemetic treatments, which primarily block the nausea and vomiting signals originating in the stomach. (hospitalhealthcare.com)
  • The treatments are interchangeable, says the study's lead author, Dr. Carlos Barcenas, from the department of Breast Medical Oncology at MD Anderson, so knowing which ones are associated with more toxicity may help some patients and doctors to choose more tolerable therapies. (time.com)
  • The results, published in the Journal of Clinical Oncology , should help patients to be more informed about their chemotherapy options, says Barcenas, and prompt more research into ways that the right treatments can be matched to the right patients. (time.com)
  • One patient treated with radiationtherapy alone had fatal esophageal toxicity. (cancernetwork.com)
  • Determine the toxicity of this drug in these patients. (knowcancer.com)
  • Patients who achieve partial response or stable disease after completion of course 2 receive additional courses in the absence of disease progression or unacceptable toxicity. (knowcancer.com)
  • Patients who achieve complete response may receive additional courses, at the discretion of the protocol investigator, in the absence of disease progression or unacceptable toxicity. (knowcancer.com)
  • Chemotherapy-induced nausea and vomiting (CINV) is a non-hematologic toxicity of chemotherapy that severely impairs the quality of life of patients and reduces their treatment compliance. (medscape.com)
  • ABSTRACT Limited research has been devoted to quality of life (QOL) of cancer patients in develop- ing countries. (who.int)
  • APF530 versus ondansetron regimens achieved numerically better CINV control in delayed and overall (0-120 hours) phases for CR, complete control, total response, rescue medication use, and proportion with no nausea. (nih.gov)
  • These findings are important because moderately emetogenic chemotherapies are used in diverse patient populations, and adequate control of nausea and vomiting remains a significant challenge with these agents. (hospitalhealthcare.com)
  • Despite significant progress in its management, nausea and vomiting continues to affect around eight in 10 cancer patients receiving chemotherapy and remains one of the most feared side-effects of the treatment. (hospitalhealthcare.com)
  • Determine the antitumor activity of docetaxel in patients with persistent or recurrent squamous cell carcinoma of the cervix. (knowcancer.com)
  • In November 2014, the FDA approved bevacizumab (Avastin) for platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or peritoneal cancers in patients who received no more than two prior chemotherapy regimens. (medscape.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • As this research continues to develop and evolve, the enhanced use of precision oncology in cancer treatment ultimately aims to improve prognosis and outcomes for patients. (biomedcentral.com)
  • However, as the outcomes for patients with low- and intermediate-risk disease are similar, these categories have been collapsed into one and considered as low-risk disease. (nature.com)
  • Clinicians may in future be able to test for such mutations to have a better gauge of chemotherapy outcomes for patients with non-Hodgkin lymphoma. (eurekalert.org)
  • The optimal chemotherapy regimen is unclear. (uni-koeln.de)
  • In breast cancer patients, it is unclear whether measuring p53, mdm-2, or p21 expression provides information on how patients will respond to chemotherapy. (lu.se)
  • Lymphoblastic lymphoma is aggressive and progresses rapidly, presenting as stage IV disease in more than 70% of patients (see Staging). (medscape.com)
  • It should be noted that many clinical trials in CLL represent a younger population, which can tolerate aggressive chemotherapy regimens to show impressive results. (medscape.com)
  • This will potentially be of benefit in opening up appropriate clinical trial opportunities for this subset of patients in the future. (cancernetwork.com)
  • Because of the disseminated nature of the disease, primary peritoneal cancer is treated with surgical debulking and chemotherapy. (medscape.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • Two (0.5%) patients and 32 (8.1%) patients had dose delayed due to febrile neutropenia and neutropenia, respectively. (hindawi.com)
  • Four (1.0%) patients and 32 (8.1%) patients had a dose changed due to febrile neutropenia and neutropenia, respectively. (hindawi.com)
  • There is strong and consistent clinical evidence to show that granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia and therefore complicated neutropenia and can be used to maintain chemotherapy at the desired dose intensity or density and minimize delays in treatment [ 11 ]. (hindawi.com)
  • Growth factors may be used to decrease the duration of neutropenia following chemotherapy. (medscape.com)
  • CONCLUSION: At a minimum of 5-year followup, there is significant decrease in loco-regional relapse with the use of extended field in high risk resected esophageal cancer patients. (bepress.com)
  • Because of the limited data available on the according to the standard regimen [12]. (who.int)
  • Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment. (stanford.edu)
  • Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? (medscape.com)
  • APF530 plus fosaprepitant and dexamethasone effectively prevented CINV among patients receiving AC-based HEC, a large subgroup in whom CINV control has traditionally been challenging. (nih.gov)
  • A propensity score-matched cohort of 6856 elderly (≥65 years) ovarian cancer patients diagnosed from 1991 to 2005 from the Surveillance, Epidemiology, and End Results-Medicare data cohort were included. (rti.org)
  • Following elderly ovarian cancer patients over a lifetime using real-world longitudinal data and adjusting for quality of life, we found that treatment with platinum-based regimen was the most cost-effective treatment alternative. (rti.org)
  • Results Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. (thieme-connect.de)
  • MOC is mostly diagnosed in patients at a younger age than patients with other types of epithelial ovarian cancers and the only clinical risk factor associated is tobacco smoking. (thieme-connect.de)
  • Patients in this study are given a presence of fungi, but results were negative. (cdc.gov)
  • Updated results will also be presented from a phase 1 study of the investigational agent SEA-BCMA in patients with relapsed/refractory multiple myeloma. (businesswire.com)
  • Results: A total of 336 patients were enrolled (48 centers, arms A/B: n = 182/154). (uni-koeln.de)
  • Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results. (thieme-connect.de)
  • It is important to realize that patients with high risk molar pregnancy receive treatment with combination chemotherapy consisting of methotrexate, dactinomycin and chlorambucil. (nethealthbook.com)
  • Patients who have contraindication to the lymphodepletion chemotherapy regimen. (moffitt.org)